Clinical trial
Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal…
NCT03835975 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT03835975 |
|---|---|
| Title | Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination |
| Official title | A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pneumococcal Disease |
| Intervention type | Biological |
| Interventions | 13vPnC, PPSV23, 20vPnC |
| Enrollment | 875 |
| Start date | Feb 12, 2019 |
| Primary completion | Feb 12, 2020 |
| Completion | Feb 12, 2020 |
| First posted | Feb 11, 2019 |
| Last update posted | Feb 21, 2021 |
| Countries | Sweden, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: